Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

    NEW YORK, Dec. 11 /PRNewswire-FirstCall/ --

    -- Innovation and Patient-Centered Approach Expected to Drive Future
       Success
    -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales
       and Is Fastest Growing in U.S.
    -- FIPNet Strategy Expands Global Reach and Improves R&D Productivity
    -- Company Aims to Reduce Cost of Bringing New Medicine to Market from
       $1.2 Billion to $800 Million by 2010.
    -- R&D Pipeline Boasts Unprecedented 59 Molecules in Clinical Development
    -- Investment in Biotechnology Capabilities Results in Expanded Large
       Molecule Portfolio
    -- ImClone Acquisition Creates Leading Oncology Franchise
    -- 2009 EPS Guidance Set at $4.00 to $4.25, Including $.30 to $.35 of
       ImClone Dilution
    -- Excluding ImClone Dilution, 2009 EPS Expected to be $4.35 to $4.55

At its annual meeting with the investment community, Eli Lilly and Company (NYSE: LLY) today highlighted progress on its expanding pipeline of innovative molecules and marketed medicines, provided investors with sales and earnings guidance for 2009, and reviewed the transformation efforts that the company is making to excel in an increasingly challenging healthcare environment.

"Lilly continues to deliver strong financial results to our shareholders through an attractive combination of volume-based sales growth for key marketed products and an ongoing commitment to productivity and cost containment," commented John C. Lechleiter, Ph.D., Lilly's president and chief executive officer. "Our scientists are dedicated to maximizing the potential of our pipeline, which now boasts an unprecedented 59 molecules in clinical development, 40 percent of which are biotech-based. Lilly's success depends on innovation, and the promising molecules we are discussing at today's m
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
(Date:9/21/2014)... For the first time, scientists have discovered how to ... strength and stiffness greater than that of today,s strongest ... a research team led by John V. Badding, a ... published in the 21 September 2014 issue of the ... point of view, our discovery is intriguing because the ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
... FRANCISCO, Calif., Oct. 25 Cell,Genesys, Inc. (Nasdaq: ... and chief executive officer, and Sharon E. Tetlow, senior,vice ... host a,conference call relating to the company,s third quarter ... on Thursday, November 1,2007, at 2:00 p.m. PT/ 5:00 ...
... will Include World-Renowned RNase and RNA Researchers, ... mechanics of ribonuclease (RNase) therapeutics will be the ... hosted by Alfacell,Corporation (Nasdaq: ACEL ). ... chief,executive officer, and David Sidransky, M.D., Alfacell,s scientific,advisory ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... will study the unique bioelectric signaling system of the ... health. The OU researcher is working to understand ... the signals used to map the world around them. ... of 500-600 discharges a second throughout their lives. ... extreme, but necessary for survival. , "There is evidence ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... Indians of Panama, an international team of scientists ... part, responsible, for the heart-healthy benefits of certain ... who are from the University of California, Davis; ... Medical School, hope the findings will lead to ...
... "fingerprinting" techniques, two University of Minnesota researchers have become ... plants with genetic markers. , Hemp, a crop ... the most abundant illegal drug of abuse in the ... They differ in levels of the psychoactive drug tetrahydrocannabinol ...
... used for genetics-versus-environment studies has joined the panoply of ... genomes have been sequenced. , At the Daphnia Genomics ... and Joint Genome Institute scientists announced they've completed a ... as it's better known to high school biology students. ...
Cached Biology News:Heart-healthy compound in chocolate identified 2New DNA 'fingerprinting' technique separates hemp from marijuana 2Genome sequencing is for ecologists, too 2
...
Candida (IgG) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
Biology Products: